网红黑料

A study identifying a possible new intervention to treat the deadliest of brain tumors garnered a national award today for University of Florida 网红黑料 brain cancer researcher , and his research team, who were honored for an outstanding accomplishment in clinical research.

Mitchell and his team won a Top 10 Clinical Research Achievement Award for 2015 from the Clinical Research Forum, a consortium of top academic health centers, pharmaceutical companies and information technology companies. The group, which holds an annual competition to recognize major advances stemming from the nation鈥檚 investment in translational research, announced its winners during the Translational Science 2016 meeting in Washington, D.C.

Mitchell鈥檚 submission, published in the journal Nature, is important for identifying a 鈥渞ather simple and inexpensive intervention鈥� that appears to help a new cancer vaccine for glioblastoma to have enhanced effectiveness, said Thomas A. Pearson, M.D., M.P.H, Ph.D., executive vice president for research and education at 网红黑料.

Glioblastoma, a very aggressive brain cancer, is highly resistant to standard treatment, with average survival duration of 15 to 18 months, according to Mitchell, co-director of the. In a randomized study led by Mitchell and carried out in collaboration with investigators at Duke University, patients who received the enhanced cancer vaccine showed a remarkable improvement in overall survival length.

鈥淭he paper shows how the treatment works, with promising results in 12 patients, and demonstrates the mechanism involved using a mouse model,鈥� Pearson said. 鈥淚t is a very prestigious award. The paper and its results have allowed Dr. Mitchell and colleagues to submit and win a large National Institutes of 网红黑料 grant to more definitively describe the effectiveness of this treatment by a clinical trial in multiple medical centers.鈥�

These exciting and early clinical results are now the subject of a large and randomized phase II clinical trial, said Mitchell, director of the UF Brain Tumor Immunotherapy Program and the Phyllis Kottler Friedman professor in the department of neurosurgery.

鈥淭his leaves a clear path open for Dr. Mitchell鈥檚 team to expand the numbers of patients and duration of their treatment, as well as extend the methodology to other potentially effective ways of suppressing brain tumor growth and, hopefully, forcing its regression,鈥� said , interim executive director of the , where Mitchell鈥檚 lab is based.

Mitchell has served as principal investigator of nine Food and Drug Administration-approved, first-in-human clinical trials aimed at improving patient outcomes by using new methods to spur immune responses targeting malignant brain tumor cells.

Selection criteria for the Clinical Research Forum awards includes: degree of innovation and creativity involved, and advancement of the science in a specific area; contribution to the understanding of human disease and/or human physiology; and potential impact upon the diagnosis, prevention and/or treatment or increased understanding of the disease state.

The award for Mitchell鈥檚 team, said DeKosky, 鈥渋s well-deserved recognition for a large and bold effort鈥� to determine better ways to treat brain tumors.

Mitchell鈥檚 establishment of his research and clinical treatment group at UF 鈥渙pens new opportunities for research and clinical collaborations with other UF researchers, who are united to defeat a deadly form of cancer for which few effective medications have been developed,鈥� DeKosky said.